14 October 2024
GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps · Primary endpoints met with statistically significant reduction in…
10 October 2024
Statement: Zantac (ranitidine) litigation – settlement agreements reached · GSK to resolve 93% (approximately 80,000 cases) of U.S. state court Zantac product liability cases for…
7 October 2024
7 October 2024 AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy AstraZeneca has entered into an exclusive license agreement…
26 September 2024
Halma plc Trading update Halma, the global group of life-saving technology companies focused on growing a safer, cleaner and healthier future for everyone, every…
25 September 2024
25 September 2024 LONDONMETRIC PROPERTY PLC LONDONMETRIC ACQUIRES Urban logistics portfolio for £78 million and continues sell down of non core assets LondonMetric Property Plc (“LondonMetric”)…
24 September 2024
GSK’s Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion · If approved, the fully liquid presentation will offer healthcare providers an…
23 September 2024
23 September 2024 Fasenra recommended for approval in the EU by CHMP for the treatment of eosinophilic granulomatosis with polyangiitis New indication supported by the…
23 September 2024 Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III…